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Abstract 
Tissue destruction i atherosclerosis is partly due to uncontrolled protease and oxygen radical release. In this study we investigated the 
release of elastase and myeloperoxidase, aswell as the production of reactive oxygen species by polymorphonuclear l ukocytes (PMNLs) 
obtained from patients with obliterative atherosclerosis of the lower legs. In addition we measured the plasma concentration f xanthine 
oxidase. PMNLs of atherosclerotic patients have a greater ability to increase lastase and myeloperoxidase r lease after their stimulation 
with formyl-methionin-leucyl-phenylalanin (fMLP) and calcium ionophore, A23187, independently of their age, than PMNLs of healthy 
middle-aged subjects. Similarly to healthy elderly subjects there was an increased superoxide anion (O 2) production under basal 
condition in both atherosclerotic patient age-groups. The activation of PMNLs with fMLP and A23187 enhanced 0 2 formation both in 
healthy subjects and in patients with atherosclerotic disease of the lower legs, however the increase was significantly ess in the latter 
group. No biochemical parameters showed significant correlation with patient's risk factors, however myeloperoxidase production was 
significantly higher in less severe stage of the disease (P < 0.05). We found that patients with atherosclerotic disease of the lower legs 
have higher plasma xanthine oxidase level than control subjects. This study indicates an other piece of evidence suggesting the activation 
and involvement of neutrophils in the pathogenesis of atherosclerosis of the lower legs. The similar tendencies in the reactivity of 
neutrophils during aging and in atherosclerosis suggest hat atherosclerosis may be an early aging process. 
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1. Introduction 
Human phagocytic cells (monocytes and polymor- 
phonuclear leukocytes) beside their role to eliminate mi- 
croorganisms by phagocytosis, followed by intracellular 
killing are also responsible for severe tissue destruction 
under pathological conditions such as inflammation, 
atherosclerosis and tumor spread. These deleterious effects 
of phagocytic ells result from the release of free radicals 
such as superoxide anion (0 2) and hydrogene peroxide 
(H202), as well as of neutrophilic granular contents, in- 
cluding potent proteolytic enzymes e.g. elastase. The un- 
controlled release of elastase is able to attack the elastic 
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fibres of the arterial wall [1-4] which play an important 
role not only in providing structural support, but also by 
modulating cell functions [5]. This destruction results in 
the liberation of soluble elastin peptides. It was demon- 
strated that elastin peptides have marked biological effects 
on PMNLs as well as on monocytes, fibroblasts and 
smooth muscle cells such as migration, aggregation, de- 
granulation and generation of oxygen radicals, thus, sug- 
gesting that they may influence cells which are involved in 
the pathogenesis of atherosclerosis [6-11]. Moreover, 
PMNLs are able to cause arterial damage by an additional 
mechanism, namely the released elastase enhances the 
conversion of endothelial xanthin dehydrogenase (XD) to 
xanthin oxydase (XO) [12,13]. XO in the presence of 
xanthin reduces O z to O 2 which in turn may reduce 
intracellular Fe 3+ to Fe z+, permitting the Fenton reaction 
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to occur, resulting in the generation of highly toxic hy- 
droxyl radical (OH). 
We found previously [14], that the susceptibility of 
purified elastin to enzymatic hydrolysis increased with the 
severity of atherosclerosis and in the mean time the amount 
of soluble elastin peptides howed a marked enhancement 
in the sera of atherosclerotic patients measured by ELISA 
and DOT immunobinding [15-17], further supporting the 
hypothesis that elastic fibres degradation may be acceler- 
ated during the atherosclerotic process. Beside the decrease 
of the rate of elastin biosynthesis a concomitant progres- 
sive increase in elastase activity may explain the disap- 
pearance of crosslinked elastin from the vessel wall. In- 
deed, in our earlier work we showed a higher elastase 
content in PMNLs of the atherosclerotic group compared 
to the control group [18]. Furthermore, it is supposed that 
during the proteolytic damage it is not the serum elastase 
level, but the amount of the released elastase by stimulated 
cells, such as PMNLs, that may be the crucial factor in 
tissue damage. To confirm this altered process of degranu- 
lation in atherosclerosis we decided to investigate the 
release of elastase from activated PMNLs, As the degranu- 
lation is accompanied by the generation in PMNLs of 
other biochemical processes uch as the oxidative burst, 
leading to inflammatory reactions, we measured also the 
superoxide anion and H20 2 productions, as well as the 
myeloperoxidase release after chemotactic peptides (fMLP 
and K-elastin) and calcium ionophore, A23187 stimula- 
tions in patients who were suffering from atherosclerotic 
vascular disease. There exists an immunochemical evi- 
dence for the presence of XO in the cytoplasm of vascular 
endothelial cells which is released into the blood stream 
only after disrupture of the cell, a well-known phe- 
nomenon during atherogenesis [19,20]. Thus, we also de- 
termined the activity of xanthin oxidase (XO) in the 
plasma which could then reflect the degree of capillary 
endothelial lesion. 
2. Materials and methods 
2.1. Patients 
52 patients with clinical signs of peripheral obstructive 
atherosclerotic disease were selected from our outpatient 
clinic to participate in this study. All patients met the 
following criteria. (1) Peripheral obstructive atherosclerotic 
disease had to be detected with Doppler ultrasonography 
and/or angiography before the patient entered into the 
study. Nevertheless all patients underwent an extensive 
vascular staging to determine whether the atherosclerosis 
was generalized. All patients exercised on a bicycle er- 
gometer according to the Bruce protocol. In case of inca- 
pacity a Dipyridamol-thallium i aging was performed to 
detect coronary arter disease. The disease of the carotid 
bifurcation was studied by a combination of B-mode imag- 
ing and pulsed Doppler system using ATL ultramark UV 
Duplex scanner. Patients who had only peripheral obstruc- 
tive arterial disease without any generalized manifestation 
of the atherosclerotic process were included in the present 
study. No patients took drugs known to influence PMNLs 
functions. (2) No clinical and spirometric evidence for the 
existence of chronic obstructive pulmonary disease; (3) 
negative smoking history or a cease of smoking since at 
least one year before taking part in the study and (4) 
obtention of informed consent from all participants. 
Claudicators were stratified into three categories corre- 
sponding to the disease severity. Claudication judged as 
'mild', 'moderate' and 'severe' were classified using the 
ankle/brachial pressure index (API = Doppler derived tib- 
ial arterial pressure indexed to the brachial arterial blood 
pressure, normal value more than 1.0). API was less than 
0.75 but more than 0.50 in cases of mild severity, while 
API was between 0.49-0.20 in moderate cases. In the case 
of severe claudication, API was less than 0.19. Distribution 
of gender, risk factors and lipid values did not differ 
significantly in the groups although age increased slightly 
with disease severity without statistical significance. A 
group of 40 healthy volunteers, matched for age, sex, lipid 
values and smoking habits, was taken as a control group. 
2.2. PMNLs 
Separation of PMNLs was routinely carried out as 
previously described [18,21]. Briefly: PMNLs were iso- 
lated from whole heparinized venous blood. Cells were 
separated by Ficoll-Hypaque density centrifugation, fol- 
lowing dextran sedimentation, of the PMNLs rich pellet. 
Contaminating erythrocytes were removed by hypotonic 
lysis. Neutrophils were then washed three times with 
Hank's balanced salt solution and resuspended in HBSS, 
and immediately tested for superoxide anion release. 
PMNLs purity over 95% and cell viability greater than 
98% were microscopically determined by Giemsa staining 
and trypan blue exclusion, respectively. All incubations 
were performed in CO 2 (5%), air (95%), humidity (95%) 
at 37°C. 
2.3. Experimental conditions 
To stimulate PMNLs we used fMLP (10 ~ M), a 
synthetic hemotactic peptide. In nonadherent PMNL, mi- 
crofilaments ordinarily restrain enzyme secretion. Since 
cytochalasin i terfere with the contractile forces generated 
by cytoplasmatic actin this drug may allow to remove the 
restraints, and thus permit the release of enzymes into the 
cell's environment. Another agent that we used to stimu- 
late the elastase release was calcium ionophore, A23187, 
agent hat is able to raise intracellular calcium level which 
promotes ecretion from azurophil granules. A23187 agent 
in 1 ~M concentration mostly stimulates ecretion from 
specific granules that contain, e.g. lactoferrin, B~2 binding 
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protein, but not proteases and myeloperoxidase [22]. 
Therefore, 10 txM calcium ionophore A23187 was used 
because it is enabled the release of substances from both 
azurophil and specific granules. 
Human PMNLs (2 × 10 6 cells/ml) were stimulated in 
Hank's buffer with A23187 or cytochalasin B (Cyt B) plus 
tMLP. We incubated PMNLs using different methods: (1) 
in the presence or absence of 10 IxM A23187 for 30 min at 
37°C; (2) in the presence or absence of 10 txM Cyt B for 
80 min at 37°C; (3) in the presence of 10 IxM Cyt B for 20 
min, and after adding 0.01 IxM fMLP, further 60 min at 
37°C. 
Incubated PMNLs were pelleted by centrifugation (500 
g for 5 min at 4°C) and the supernatant were assayed for 
neutrophil elastase and myeloperoxidase activity. 
2.4. Assay of human leukocyte lastase (HLE) activity 
Enzyme assay was carried out according to the method 
of Hornebeck et al. [23,30] slightly modified by us [16]. 
Briefly: Elastase activity was measured with 1 mM Meo- 
Suc-Ala-Ala-Pro-Val-pNa (Sigma) dissolved in dimethyl 
sulfoxide in Hepes buffer at pH 7.5 containing 0.5 M NaCI 
and 10% DMSO at 37°C. Elastase activity was expressed 
as nmoles of substrata cleaved per minute assuming an 
extinction coefficient of 8.8 x l03 M -~ cm -~ at 405 nm. 
2.5. Assay of neutrophil myeloperoxidase (MPO) act±riO, 
Myeloperoxidase activity was measured using the 
method of Bretz et al. [24]. with 0.32 mM o-dianisidine 
(3,3-dimethoxybenzidine, Fluka) in citrate buffer, pH 5.5, 
containing 0.08 mM hydrogen peroxide. The reaction was 
stopped with 35% perchloric acid. The enzyme activity 
was expressed as nanomoles of product per minute assum- 
ing an extinction coefficient of 2 × t0  4 M- ~ cm- ~ at 560 
rim. 
2.6. Superoxide anion Of  production and hydrogen per- 
oxide (H 2 0 2 ) release 
This was determined according to the method of Babior 
et al. [25] as previously described. Briefly, neutrophils 
(2.5 X 10 6 cells) were incubated (37°C, 15 min) with 0.01 
IxM fMLP (Sigma) or 10 IxM calcium ionophore, A23187 
(Sigma) or kappa elastin in 1.0 ixg/ml concentration. 
Kappa elastin was prepared from bovine ligamentum 
nuchae elastic by alkaline hydrolysis in ethanol as previ- 
ously described by L. Robert in 1968 [26]. Incubation was 
carried out in the presence of 50 IxM ferricytochrome c 
(Sigma, type III). Parallel tubes, with the same compo- 
nents, included also 300 U/ml  superoxide dismutase (SOD, 
type I, Sigma). After incubation, the tubes were subse- 
quently centrifuged (400 X g, 10 min, 4°C). The superox- 
±de production was determined from the O.D. 550 of the 
supernatants without SOD minus the O.D. 550 of matched 
samples with SOD, using an extinction coefficient of 
2.1 × 10 4 M 1 cm- ' .  The results were expressed as nmol 
O~/106 cells per min [27]. 
2.7. Measurement ofxanthine oxidase (XO) activi~ 
XO activity was measured according to the method of 
Hainig and Legan [28] and Beckman et al. [29]. Briefly: 
plasma samples were assayed for their XO activity using 
2-amino-4-hydroxypteridine (AHP) as substrate in a spec- 
trofluorimeter (Perk±n-Elmer MPF 44B) with excitation at 
345 nm and emission at 390 nm. The volume of the assay 
mixture was 2.0 ml in PBS which consisted of 200 ixl 
substrate and putative nzyme from samples (25 txl). Reac- 
tion proceeded for 60 rain at 37°C. The concentration of
isoxanthopterin formed was calculated from the linear 
relationship between fluorescence intensity versus its con- 
centration in 0-10 nmol of the product. The buffer-sub- 
strate was prepared on the day of use by diluting a stock 
Table 1 
Secreted human leukocyte lastase and myeloperoxidase from granulocytes separated from healthy and atherosclerotic middle-aged subjects, stimulated 
with various stimuli 
Stimuli Released protease by granulocytes: 
human leukocyte lastase (nmol/min per 106 cells) 
healthy (middle aged) atherosclerotic (middle aged) 
myeloperoxidase (nmol/min per 106 cells) 
healthy (middle aged) atherosclerotic (middle aged) 
Age (yrs) 46.3 ± 3.4 47.6 + 5.1 46.3 _ 3.4 47.6 __. 5.1 
Resting 1.8 ± 0.15 0.54 + 0.05 1.34 ± 0.10 0.95 ± 0.11 
CytB 1.46 ± 0.09 1.32 -+ 0.81 0.99 ± 0.07 1.16 + 0.12 
A23187 7.56 + 1.06 13.23 _+ 1.44 * 4.865 +_ 0.43 7.695 -/-_ 0.65 
CytB(+ fLMP) 11.10 _ 1.32 24.75 + 1.83 * 5.86 ± 0.61 10.795 _+ 1.17 " 
Human granulocytes (2 x 106 cells/ml) were stimulated in Hank's puffer with A23187 (10 p,M) for 30 min at 37°C or with cythochalasin B (0.1 ixM) in 
the presence and absence of formyl-methionilleucyl-phenylalanine (0.01 IxM) for 80 min at 37°C. The incubated granulocytes were pelleted and the 
supernatants were assayed for human leukocyte lastase with MeoSuc-Ala-Ala-Pro-Val-pNa (Sigma) and myeloperoxidase using 3,3-dimethoxybenzidine 
(Fluka). Enzymes activity were expressed as nmol of substrate cleaved per minute or nmol of product per minute assuming extinction coefficients of 
8.8 )< 103 M -I cm -] at 405 nm or 2 X 104 M -I cm -1 at 560 nm, respectively. Data represent mean + SD. 
* P < 0.05 statistically significant as compared to healthy middle aged subject. 
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solution as desired with phosphate buffer (0.2 M, pH 7.2). 
The stock solution was prepared by dissolving 14.68 mg 
pulverized AHP with a few drops of 0.2 N NaOH, then 
diluting to 100 ml with distilled water. The stock solution 
9 × 10 4 M was kept frozen between usage. 
3. Statistical analysis 
All biochemical values were expressed as means _+ SD. 
Statistical difference was determined by Student's t-test, 
with significance defined as P < 0.05. 
Table 2 
Clinical characteristics of the studied patient populations and the release 
of elastase and myeloperoxidase from stimulated PMNLs in relation to 
severity of the disease stages 
Doppler index 0.75-0.50 0.49 >> 0.20 < 0.20 
No. (male/ female)  19 (14/5)  22 (18/4)  11 (7 /4 )  
Age (yr) 52.5 + 7.9 53.6 ± 11.3 56.5 ± I I 
Human leukocyte lastase 
(nmol /min  per 10 ~ cells) 
IMLP 26.61 _+2.76 20.19_+2.47 19.33±2.5 
A23187 16.39_+1.46 10,87_+0.96 7.45+0.66 
Myeloperoxidase 
(nmol /min  per I() ~ cells) 
tMLP 12.68_+ 1.17 9.14_+0.97 8.82_+ 1.45 
A23187 11.16+1.71 6.215_+2.56 4.76_+0.44 .... 
4. Results 
4. l. Elastase and myeloperoxidase r lease 
Our results documenting the elastase and myeloperoxi- 
dase release from PMNLs under various stimuli are shown 
in Table 1. In our present experiment, Cyt B did not cause 
significant enzyme release from PMNLs obtained from 
both healthy and atherosclerotic patients. A23187 alone, 
and fMLP in the presence of Cyt B, induced a significant 
release of elastase (P < 0.05) in atherosclerotic patients in 
contrast o the age-matched controls. In studying the age- 
related association of this parameter, a marked aged depen- 
dent increase of the elastase release was found in healthy 
subjects ( r= 0.91, P < 0.05) (Fig. 1). Furthermore, this 
response was more pronounced in the subgroup of healthy 
elderly of 75 yr and over, and did not differ from the 
response of PMNLs derived from elderly atherosclerotic 
patients (data not shown). The stimulated release of 
myeloperoxidase was significantly higher in athero- 
sclerotic than in healthy middle aged subjects (P < 0.05). 
Similar to the elastase, the release of MPO was also 
enhanced uring the aging process (data not shown). 
Patients uffered from obliterativ atherosclerotic disease of the lower legs 
were stratified into the mild (0.75-0.50), moderate (0.49 >> 0.20) and 
severe ( << 0.20) stages of the disease according to the ankle/brachial  
pressure index (Doppler derived tibial pressure indexed to the brachial 
arterial pressure). All values represent the mean + SD. 
P < 0.01. Difference was significant as compared to the group of 
patients with ankle/brachial  pressure index above 0.50. 
To find out, whether isk factors and severity of the 
disease have an influence on the quantity of HLE or MPO 
released, we analyzed the correlation between protease 
release and the former parameters. An inverse correlation 
was found between protease secretion and disease severity. 
In the group of patients with mild claudication, as deter- 
mined by ADI, the quantity of released HLE as well as 
MPO was the most pronounced as compared to that in the 
moderate and severe stages of the disease. Statistically 
significant differences were only found in the case of MPO 
release in mild claudicators as compared to the values of 
severe claudicators (P < 0.05). The quantity of released 
HLE was also higher in PMNLs obtained from mild 
claudicators than that obtained from severe claudicators. 
but the difference was not statistically significant (Table 
2). 
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Fig. I. Correlation of released elastase by formyl-methionin-leucyl- 
phenylalanine (fMLP) and age of subjects. Black triangle: released elas- 
tase from granulocytes of healthy subjects ( r  = 0.91, 17 = 40, solid line), 
stars: atherosclerotic subjects ( r = 0.12, n = 52, dotted line). 
4.2. O~ production and H,O~ release 
A significant difference (P < 0.05) was found between 
the basic levels of O,- of healthy middle-aged subjects and 
of atherosclerotic patients. In the case of middle aged 
atherosclerotic subjects the resting 0 2 production was 
enhanced, while stimulation was decreased using various 
stimuli such as fMLP and K-elastin. Stimulation remained 
unaffected when we used calcium ionophore (Fig. 2). The 
0 2 production was also significantly (P < 0.05) different 
between healthy middle aged and healthy aged subjects. 
No differences were found between healthy and athero- 
sclerotic elderly subjects. The profile of O; generation of 
healthy elderly and middle aged atherosclerotic subjects 
was quite similar. 
H202 production which is not linked to receptor stimu- 
lation was diminished in the case of atherosclerotic pa- 
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Fig. 2. Superoxide anion generation in resting and stimulated granulo- 
cytes obtained from healthy middle aged (n = 24, average age: 46.3 + 3.4 
yr) and elderly healthy (n= 16, 67.5_+4.5) subjects and middle aged 
(n = 25, 47.6+_5.1) and elderly (n = 27, 70.3 + 5.5) atherosclerotic pa- 
tients. The stimulating agents were as follows: KE = K-elastin 1.0 ixg/ml, 
fMLP = formyl-leucyl-phenylalanin 0.0l ~M, A23187 = calcium 
ionophore, 10 IzM. * P < 0.05 It was compared to healthy middle aged 
subjects. Each column represents the mean+ S.D. H = healthy, ats = 
atherosclerotic. 
tients, and only a slight increase of H202 generation was 
detected in the case of healthy elderly subjects without 
statistical significance (Fig. 3.). K-Elastin significantly (P  
< 0.05) stimulated the H202 production in case of mid- 
dle-aged healthy subjects. 
4.3. Xanthin oxidase activity 
XO activity was raised in the plasma of atherosclerotic 
patients of both ages. The elevation was the most marked 
Middle aged H 
12[ I . . . . .  I 
-. 10 
~ 6 
0 
2 
Fig. 3. H202 release from granulocytes obtained from healthy and 
atherosclerotic subjects of various ages induced by K-elastin (1.0 Ixg/ml). 
Middle aged H = middle aged healthy (n = 24) or Elderly H = elderly 
healthy subjects (n = 16), Middle aged ats = middle aged atherosclerotic 
patients (n ~ 25) and elderly ats = elderly atherosclerotic patients (n = 
27). Each column represents he mean _. S.D. * P < 0.05 when compared 
to healthy middle-aged subjects. 
0 
Middle aged H Elderly H Middle aged ats Elderly ats 
Fig. 4. Plasma xanthin oxidase activity in patients with obliterative 
atherosclerotic disease of the lower legs and healthy subjects. Each 
column represents he mean ± S.D. * P < 0.05 It was compared to healthy 
middle aged subjects. 
in middle aged atherosclerotic patients and differed statisti- 
cally significantly from the healthy middle aged subjects 
(P < 0.05), however, plasma XO activity does not increase 
with age in healthy subjects (Fig. 4). 
5. Discussion 
One of the most important pathological feature of 
atherosclerosis is the degradation of elastin fibers. 
Hornebeck et al. [23] have correlated the increased elastase 
type activity in human aortic tissue with the severity of 
atherosclerosis, however the cellular origin of elastase is 
still an unresolved question. Although, vascular cells, such 
as smooth muscle cells are able to modulate the structure 
and composition of the extracellular matrix by the release 
of proteolytic enzymes (e.g. elastase), PMNLs remain the 
main source of elastase. As the released elastase is rapidly 
dissolved in the circulation, the serum elastase may not 
represent adequately the total elastase activity in pathologi- 
cal conditions [31,32]. Therefore, we choose an alternative 
approach to confirm the role of elastase in atherosclerosis. 
We have demonstrated that marked ifference xists in the 
responsiveness of PMNLs, concerning the elastase release, 
obtained from healthy and atherosclerotic middle-aged 
subjects. PMNLs obtained from atherosclerotic patients 
released significantly more elastase under fMLP and 
A23187 stimulations than those from healthy middle-aged 
subjects. Activation of PMNLs by various stimuli e.g. 
growth factors, endothelial cells, was demonstrated to in- 
duce their adhesion to endothelial cells [33-39]. The acti- 
vated and recruited PMNLs may be highly disruptive for 
the integrity of the vessel wall rendering them more sus- 
ceptible to further tissue destruction. Therefore our results 
reinforce the supposition that PMNLs may be transiently 
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present in diseased artery wall at the very beginning of the 
pathological process of atherosclerosis. 
The difference found in elastase release between healthy 
and atherosclerotic middle-aged subjects disappeared when 
we compared healthy and atherosclerotic aged subjects. 
Indeed, the elastase release showed an age related pattern 
and the disease could not further modulate it. With age 
decreased rate of elastin synthesis in the arterial wall as 
well as altered effector functions of PMNLs were demon- 
strated [40-43]. Thus, the demonstrated gradual increase in 
the elastase activity with age can further contribute to the 
disappearance of the crosslinked elastin content of the 
arterial wall. Our results suggest that these processes might 
be accelerated uring atherosclerosis already at an earlier 
age. It is of interest, that we found an inverse correlation 
between the elastase release from PMNLs and the clinical 
severity of the disease. The most marked release of elas- 
tase was shown in individuals who were at the earliest 
stage of the disease. Gminsky et al. [44] demonstrated that 
an enhanced elastin metabolism followed by an autoimmu- 
nization process towards elastin could be already detected 
in healthy children of atherosclerotic patients, underlining 
the importance to determine the role of elastase before the 
clinical manifestations of atherosclerosis. As the initial 
stages of atherosclerosis are strongly related to clinical risk 
factors and the reduction of these factors may result in 
slowing of the pathological process, the use of synthetic, 
orally active protease inhibitors could have therapeutic 
value [45]. The properties of these inhibitors allow them to 
effectively supplement the activity of natural in vivo in- 
hibitors of PMNLs elastase particularly in primary or 
secondary (e.g., smoking) deficiency of c~l-antitrypsin 
[46,47]. Moreover, antioxidants can also provide signifi- 
cant protection suggesting an interaction between reactive 
oxygen species (e.g., MPO-H202-CI system) and the elas- 
tase-antielastase (a~-antitrypsin) system. 
Another deleterious consequence of the PMNLs degran- 
ulation is the production of reactive oxygen species (ROS) 
such as O 2 that are essential for host defense, but may 
also induce tissue damage and are frequently observed in 
inflammation and atherosclerosis. We could demonstrate 
that the resting level of O] was increased, while its 
stimulation was less effective in both age-groups of athero- 
sclerotic patients, as well as in that of healthy elderly 
subjects. In contrast, PMNLs derived from middle-aged 
healthy subjects howed low resting 0 2 production with 
marked increase in 0 2 production after stimulation by 
various stimuli. After its release the O 2 rapidly dismutates 
to H202 and 02. This increased basal production of 0 2 
and the decreased stimulability of PMNLs with aging and 
in atherosclerosis suggest hat a disturbed transmembrane 
signal transduction exists through receptors e.g. fMLP at 
least for phospholipase C activation. These observations 
are however not contradictory to the finding that protease 
secretion could be still induced by fMLP. This may sup- 
port the proposal that beside G~ protein which is very 
important during the turning of the extracellular signal into 
intracellular one for O 2 production, at least two other 
different GTP binding proteins e.g. Gp or G e proteins 
could be involved in NADPH oxidase activation and in 
exocytosis thus, allowing alternative signaling pathways to 
occur [48]. 
The H20 2, which is generated secondary from the 
dismutation of 0 2 may be further connected to the form- 
ing of hypochlorous acids (HOC1, HOBr) in the presence 
of chloride and bromide during interaction with myeloper- 
oxidase (MPO) [1,22]. The production of the H202 origi- 
nating directly from stimulation with KE was found to be 
lower in atherosclerotic patients compared to healthy sub- 
jects. Actually we do not have any plausible explanation 
for this result. Theoretically, the presence of an intra- 
cellular H2Oz-scavenging system or an enhanced MPO 
activity could lead to an underestimation f the amount of 
H202. The MPO, which is also released from lysosomes 
during stimulation was found significantly higher after 
fMLP stimulation in both middle-aged atherosclerotic pa- 
tients and healthy elderly subjects, compared to healthy 
middle-aged subjects. We can not say actually that the 
cause of the lower H202 value might be the result of the 
elevated intracellular MPO content, but further investiga- 
tions are needed to confirm this hypothesis. According to 
our results, the xanthin oxidase (XO) activity could be 
demonstrated in the plasma of both healthy and athero- 
sclerotic subjects, however the XO activity was signifi- 
cantly higher in middle-aged atherosclerotic patients than 
in healthy control subjects. These results could be further 
confirmed by the following evidences. 1. We measured 
whether the XO activity could have come from PMNLs or 
other blood cells, but we failed to show any XO activity. 2. 
We studied the inhibition of the reaction in the presence of 
the specific XO inhibitor, the allopurinol, which was able 
to effectively prevent he XO activity. 3. We tested our 
method in case of hepatocellular damage, where our method 
could effectively demonstrated the well known elevated 
XO activity. Despite of the fact that, Jarash et al. [19] 
failed to show any xanthin oxidase activity in human sera 
even in patients with diabetic microangiopathy, XO ap- 
peared in the effluent blood of the involved tissue during 
ischemia reperfusion [49]. Moreover, antibodies against 
XO could arise during myocardial infarction, suggesting a 
pathogenic role of XO in these disease states. We need 
further studies to determine the exact pathologic signifi- 
cance of the plasma XO in atherosclerosis. 
In summary, our results indicate that the amount of 
elastase as well as of myeloperoxidase released by various 
stimuli increased in middle-aged atherosclerotic patients. 
We found that the elastase release was also enhanced in 
healthy elderly subjects, demonstrating an age-related as- 
sociation between these parameters. According to our re- 
sults, we suggest hat if enhanced proteolytic activity is of 
pathogenic importance in atherosclerosis it is likely to be 
due to an increased quantity of released proteolytic en- 
216 A. Moh{tcsi et al. / Biochimica et Biophysica Acre 1316 (1996) 210-216 
zyme from peripheral  PMNLs ,  already at the early stage of 
the disease. Our  results concern ing the superoxide anion 
product ion indicate that the elevated rest ing superoxide 
anion release might  also contr ibute to the putative harmful  
effects of PMNLs  in atherosclerosis.  This high XO level in 
the p lasma of atherosclerot ic patients might  represent an 
increased endothel ia l  damage,  but this hypothesis  should 
be further elucidated. Finally, our f indings demonstrat ing 
simi lar patterns for protease release and ROS product ion 
by PMNLs ,  after fMLP  st imulat ion,  obta ined f rom healthy 
elderly and middle-aged atherosclerot ic subjects suggest 
that atherosclerosis  might  be an early aging process. 
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